Literature DB >> 9883867

P/Q-type voltage-gated calcium channel antibodies in paraneoplastic disorders of the central nervous system.

R Voltz1, A F Carpentier, M R Rosenfeld, J B Posner, J Dalmau.   

Abstract

Whether P/Q-type voltage-gated calcium channel (VGCC) antibodies are present in the serum of patients with paraneoplastic syndromes other than the Lambert-Eaton myasthenic syndrome (LEMS) and tumors other than small-cell lung cancer (SCLC) is controversial. Using a commercially available radioimmunoprecipitation assay kit, we examined the sera of 93 patients with paraneoplastic syndromes of the central nervous system (CNS), including 27 patients with paraneoplastic cerebellar degeneration (PCD) associated with tumors other than SCLC and 66 SCLC patients with paraneoplastic encephalomyelitis and sensory neuronopathy (PEM/SN). All PCD sera from patients with tumors other than SCLC were negative for P/Q-type VGCC antibodies. Eight of 66 (12%) SCLC patients with PEM/SN had P/Q-type VGCC antibodies; 4 had LEMS and the other 4 had no symptoms of LEMS or they were overlooked and, therefore, not examined electrophysiologically. In patients with paraneoplastic syndromes of the CNS, the detection of P/Q-type VGCC antibodies supports the diagnosis of LEMS; in our series, only 6% of patients with SCLC and PEM/SN may have had a false positive antibody result, or undiagnosed LEMS.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9883867     DOI: 10.1002/(sici)1097-4598(199901)22:1<119::aid-mus19>3.0.co;2-5

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  11 in total

1.  Paraneoplastic and other autoimmune disorders of the central nervous system.

Authors:  Viroj Wiwanitkit
Journal:  Neurohospitalist       Date:  2014-01

2.  Update on paraneoplastic neurologic disorders.

Authors:  Myrna R Rosenfeld; Josep Dalmau
Journal:  Oncologist       Date:  2010-05-17

3.  Ataxia associated with Hashimoto's disease: progressive non-familial adult onset cerebellar degeneration with autoimmune thyroiditis.

Authors:  M Selim; D A Drachman
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-07       Impact factor: 10.154

4.  Functional properties of a new voltage-dependent calcium channel alpha(2)delta auxiliary subunit gene (CACNA2D2).

Authors:  B Gao; Y Sekido; A Maximov; M Saad; E Forgacs; F Latif; M H Wei; M Lerman; J H Lee; E Perez-Reyes; I Bezprozvanny; J D Minna
Journal:  J Biol Chem       Date:  2000-04-21       Impact factor: 5.157

Review 5.  Antibody testing as a diagnostic tool in autonomic disorders.

Authors:  Steven Vernino
Journal:  Clin Auton Res       Date:  2008-08-22       Impact factor: 4.435

6.  Clinical and organizational factors in the initial evaluation of patients with lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.

Authors:  David E Ost; Sai-Ching Jim Yeung; Lynn T Tanoue; Michael K Gould
Journal:  Chest       Date:  2013-05       Impact factor: 9.410

Review 7.  The Lambert-Eaton myasthenic syndrome.

Authors:  A F Carpentier; J Y Delattre
Journal:  Clin Rev Allergy Immunol       Date:  2001-02       Impact factor: 10.817

Review 8.  Small-cell lung cancer-associated autoantibodies: potential applications to cancer diagnosis, early detection, and therapy.

Authors:  Meleeneh Kazarian; Ite A Laird-Offringa
Journal:  Mol Cancer       Date:  2011-03-30       Impact factor: 27.401

Review 9.  'Medusa head ataxia': the expanding spectrum of Purkinje cell antibodies in autoimmune cerebellar ataxia. Part 2: Anti-PKC-gamma, anti-GluR-delta2, anti-Ca/ARHGAP26 and anti-VGCC.

Authors:  S Jarius; B Wildemann
Journal:  J Neuroinflammation       Date:  2015-09-17       Impact factor: 8.322

10.  Antibody repertoire in paraneoplastic cerebellar degeneration and small cell lung cancer.

Authors:  Lidia Sabater; Romana Höftberger; Anna Boronat; Albert Saiz; Josep Dalmau; Francesc Graus
Journal:  PLoS One       Date:  2013-03-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.